Brought to you by 
NitroMed to develop anti-restenosis stents with Cordis
31 Jul 2015
Executive Summary
Cordis, part of J&J, will collaborate with NitroMed Inc. (pharmaceuticals based on delivery of nitric oxide to targeted tissues) to develop anti-restenosis products, starting with novel coronary stents coated with NO.
Deal Industry
- Biotechnology
- Medical Devices
- Pharmaceuticals
-
Medical Devices
- Implantable Devices
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
NitroMed to develop anti-restenosis stents with Cordis
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice